

June 13, 2025

## BrightPath to Present Data on Bispecific Antibody BP1212 for Cancer Immunotherapy at IRCI 2025

Tokyo, Japan – June 13, 2025/ -- BrightPath Biotherapeutics (TSE Growth 4954), a clinical-stage biopharmaceutical company focused on developing novel cancer therapeutics, today announced that the Company will present preclinical data on **BP1212**, a humanized bispecific antibody targeting TIM-3 and CD39, at the **Immune Response in Cancer and Infection (IRCI) 2025** conference, to be held in Lyon, France, from June 18–20, 2025.

The presentation will highlight the mechanism by which BP1212 promotes inflammasomes in dendritic cells, leading to enhanced antitumor immunity and improved response to immune checkpoint blockade.

The company believes that BP1212 represents a first-in-class therapeutic antibody aimed at clinically validating inflammasome pathway as a new strategy in cancer immunotherapy.

### [Presentation Details]

**Title:** Cancer immunotherapy by promoting inflammasomes in dendritic cells.

**Presentation Number:** 10

**Date & Time:** June 19, 2025, at 00:45 PM (CEST)

### About BrightPath:

BrightPath is a clinical stage biopharmaceutical company focused on the development of novel cancer therapies to transform cancer treatment for refractory or progressive cancers that cannot be treated with conventional standard therapies. BrightPath is actively involved in developing cell therapies, currently in clinical trials, and immunomodulatory antibodies.

For more information, visit [www.brightpathbio.com/English/](http://www.brightpathbio.com/English/)

### Investor and Media Contact:

[irpr@brightpathbio.com](mailto:irpr@brightpathbio.com)

[www.brightpathbio.com/English/](http://www.brightpathbio.com/English/)